Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2010

View Archived Issues

New Pim kinase inhibitor ARRY-770 reduces airway hyperresponsiveness in mice

Adalimumab improves quality of life in Crohn's disease patients

Evotec Neurosciences claims bradykinin B1 receptor antagonists

CETP gene polymorphism linked to reduced risk for dementia

Topical WBI-1001 improves atopic dermatitis in double-blind trial

Roche discovers new GlyT-1 inhibitors

Merck KGaA discloses novel tyrosine kinase inhibitors

Bayer Schering claims new adenosine A1 receptor antagonists

Sanofi-aventis patents new cannabinoid CB1 receptor antagonists

NIAID awards PDS phase II grant for HPV cancer vaccine

Ark withdraws Cerepro MAA after EMA's request for further trial in malignant glioma

Vernalis terminates agreement with PCH and regains rights to frovatriptan

Biotie and Pfizer to end discovery phase of development of PDE10 inhibitors for schizophrenia

Stanford University requests data from Favrille's cancer vaccine trials

Ischemix begins phase IIa CMX-2043 trial in ischemia reperfusion injury

Ista receives action date for FDA review of XiDay sNDA

Chimerix begins phase II CMX-001 study in CMV-seropositive stem cell transplant recipients

Bristol-Myers and AstraZeneca begin phase IV Onglyza trial

Enrollment begins in phase IIb trial of NTx-265 in acute ischemic stroke

mtm laboratories launches cervical cancer test CINtec Plus in Europe

Omthera to advance Epanova for hypertriglyceridemia

Celltrion develops broad-spectrum human monoclonal antibodies against influenza

Omeros licenses Asubio's PDE7 inhibitors for movement disorders

Harvard and Dana-Farber grant Acetylon exclusive license to HDAC inhibitor discovery platform

Abbott and GSK to develop molecular diagnostic test for skin cancer treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...